The CHA 2 DS 2 -VASc score (congestive heart failure, hypertension, age Ն75 years [doubled] EXPOSURES Levels of the CHA 2 DS 2 -VASc score (based on 10 possible points, with higher scores indicating higher risk), stratified by concomitant AF at baseline. Analyses took into account the competing risk of death.
H eart failure (HF) is associated with an increased risk of ischemic stroke and mortality, whether in sinus rhythm or atrial fibrillation (AF). [1] [2] [3] [4] [5] , which is recommended in current guidelines (based on 10 possible points, with higher scores indicating higher risk). 6, 7 In recent years, use of the CHA 2 DS 2 -VASc score in predicting ischemic stroke, TE, and death has extended beyond the original disease state for which it was proposed. 8, 9 In addition, it is recognized that the cluster of multiple stroke risk factors included within the CHA 2 DS 2 -VASc score increases the risk of ischemic stroke, TE, and death, whether or not AF is present. Thus, there is a need to study the extent to which concomitant AF modifies the pattern of the association between CHA 2 DS 2 -VASc score and the risk of ischemic stroke, TE, and death in patients with HF.
Evaluating an ischemic stroke and TE risk score in a population with a high mortality rate such as the HF population (5-year mortality of 45%-60%) 10, 11 is not trivial because a competing-risks setting taking careful consideration of the interplay between mortality and ischemic stroke/TE risk is needed to provide meaningful risk assessments. 12, 13 We hypothesized that the CHA 2 DS 2 -VASc score could predict ischemic stroke, TE, and death in patients with HF without AF in a manner comparable with that evident in AF populations. We hypothesized that at high CHA 2 DS 2 -VASc scores, the risk would be comparable between patients with and without AF.
Methods

Registry Data Sources
We used 3 nationwide registries in this study: (1) the Danish National Patient Register, 14 which has registered all hospital admissions along with diagnoses since 1977 and has coded all diagnoses according to the International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) since 1994; (2) the Danish National Prescription Registry, 15 which contains data on all prescriptions dispensed from Danish pharmacies since 1994, coded according to the Anatomical Therapeutic Chemical (ATC) Classification System; and (3) the Danish Civil Registration System, which holds information on date of birth, migration, vital status, date of death, and sex of all persons living in Denmark. 16 Data were linked via a unique personal identification number used in all Danish national registries. All 3 registries were used up to December 31, 2012 (end of follow-up). These registries have previously been well validated, 14, 15, 17 and the diagnoses of HF, AF, and ischemic stroke have been found to be valid. [17] [18] [19] No ethical approval is required for anonymous register studies in Denmark. The study was approved by the Danish Data Protection Agency.
Study Population
The study population was identified as patients aged 50 years or older discharged with a primary diagnosis of incident HF (ICD-10 codes I50, I42.0, I11.0, I13.0, and I13.2) in the period January 1, 2000, to December 31, 2012. Patients with AF were identified by a hospital diagnosis of AF or atrial flutter (ICD-10 code I48) between 1994 and baseline. We excluded patients treated with a vitamin K antagonist (ATC codes B01AA03 and B01AA04) within 6 months prior to the HF diagnosis. Moreover, patients with a diagnosis of cancer (ICD-10 codes C00-C97) within 5 years before HF diagnosis or with a prior diagnosis of chronic obstructive pulmonary disease (COPD [ICD-10 code J44]) were excluded.
Comorbidities at baseline were identified using the Danish National Patient Register and the Danish National Prescription Registry. Ascertainment of baseline medication status was based on medication purchase in a 45-day window before or after the date of HF diagnosis. ICD-10 codes and ATC codes were used to define comorbidities and medical therapies (eTable 1 in the Supplement).
Risk Stratification Using CHA 2 DS 2 -VASc Score Based on the CHA 2 DS 2 -VASc score, patients were given 1 point for congestive HF, hypertension, age 65 to 74 years, diabetes mellitus, vascular disease, and female sex and 2 points for age 75 years or older and previous TE. 20 Accordingly, a score of 1 in our analyses corresponds to patients with HF only and no additional stroke risk factors.
Outcomes
The primary end point was defined as a hospital diagnosis (according to the 
Statistical Analysis
Baseline characteristics at the time of HF diagnosis were described using means and standard deviations for continuous measures and percentages for categorical measures ( Table 1) . Time-to-event analysis was used to describe the association between the CHA 2 DS 2 -VASc score and the risk of ischemic stroke, TE, and death, separately within the strata of patients with HF with and without a prior diagnosis of AF. Time To enable comparison with other studies, we first calculated crude incidence rates of end points, stratified according to presence of concomitant AF. However, for the purpose of risk stratification, particularly in the context of competing risks, absolute risks (cumulative incidences/probabilities) are more relevant. 12, 13 We calculated absolute risks for all end points using the Aalen-Johansen estimator 21 to take into account competing risks of death. Relative risks according to CHA 2 DS 2 -VASc score (relative to a CHA 2 DS 2 -VASc score of 1) were also calculated using the pseudovalue method to take into account competing risks of death. 22, 23 The pseudovalue method reduces to simple regression with a log-link function on the event status indicator in the absence of censoring, whereas censored observations (for which the event status is not observed) are replaced with pseudo-observations based on Aalen-Johansen cumulative incidence estimates using the jackknife method. These methods have not been validated but are described in previous literature.
24,25
Wald P values for interactions on a risk ratio scale were used to quantify whether the overall association between CHA 2 DS 2 -VASc score and outcome risk differed between patients with and without AF.
To quantify the discriminatory properties of the CHA 2 DS 2 -VASc score, we used C statistics for each end point. This well-known measure of discrimination can be interpreted as the probability that a randomly selected patient who experiences the event of interest before a given time has a higher risk score than a control patient who does not experience an event before a given time. Because of competing risks of death, there are several valid definitions of control patients (alive and event free; alive and event free or dead) leading to different interpretations. 24, 25 We used as controls patients who were alive and event free at 1-and 5-year follow-up and used the inverse-probability-ofcensoring weighted estimator (assuming censoring and event times to be independent given CHA 2 DS 2 -VASc score).
Bootstrap confidence intervals for the C statistics were calculated using 1000 bootstrap samples. Furthermore, with the same definition of controls, we estimated for each end point the negative predictive value (NPV) of the CHA 2 DS 2 -VASc score with 1 as the cutoff; ie, the proportion of patients with CHA 2 DS 2 -VASc score = 1 who were alive and without the end point of interest at 1-and 5-year follow-up. Sensitivity analysis was performed by repeating the absolute and relative risk calculations when extending the definition of concomitant AF at baseline to presence of a prior diagnosis of AF at baseline or within 30 days after HF diagnosis. This sensitivity analysis was performed because some patients might have a diagnosis of AF shortly after the HF diagnosis. Additionally, approximately 14% had a diagnosis of AF during 5 years of follow-up; thus, we performed another sensitivity analysis by repeating the absolute and relative risk calculations in the non-AF group after censoring patients who were diagnosed as having AF during follow-up. Moreover, a split sample analysis according to early (2000) (2001) (2002) (2003) (2004) (2005) and late (2006-2012) study period was performed. Finally, we performed a sensitivity analysis in which we included patients with COPD. All sensitivity analyses were compared with the main analysis. 
Results
The study population comprised 42 987 patients with HF aged 50 years or older, among whom 21.9% had a diagnosis of AF at baseline (Figure 1) . The median follow-up period with respect to ischemic stroke was 1.84 years (interquartile range, 0.22-4.59 years). The distribution of CHA 2 DS 2 -VASc scores in the study population according to presence of an AF diagnosis are shown in Table 2 .
Incidence rates during the first year are shown in Table 2 ; overall, they exhibited the same fundamental characteristics as the absolute risks, which are presented in detail below. Incidence rates were generally attenuated after 5 years of follow-up (eTable 2 in the Supplement), indicating that most events occurred relatively shortly after the HF diagnosis. Numbers of events and person-years are shown in Table 2 and eTable 2 for 1 and 5 years of follow-up, respectively.
For patients with HF with and without a diagnosis of AF, Figure 2 shows the absolute risks according to CHA 2 DS 2 -VASc during the first year after HF diagnosis, alongside the corresponding relative risks, comparing patients with a score higher than 1 with those with a score of 1 (no additional stroke risk factors). In both strata, the 1-year absolute risk generally increased with increasing CHA 2 DS 2 -VASc score but exhibited a less clear association for ischemic stroke among patients with HF and AF. For ischemic stroke and death, absolute risks were consistently higher among patients with HF and AF compared with those without AF (for ischemic stroke, with concomitant AF, 4.5%, 3.7%, 3.2%, 4.3%, 5.6%, and 8.4% and without concomitant AF, 1.5%, 1.5%, 2.0%, 3.0%, 3.7%, and 7% for scores 1-6, respectively; overall P = .001 for interaction; for all-cause death, with concomitant AF, 19.8%, 19.5%, 26.1%, 35.1%, 37.7%, and 45.5% and without concomitant AF, 7.6%, 8.3%, 17.8%, 25.6%, 27.9%, and 35.0%, for scores 1-6, respectively; overall P<.001 for interaction), but this pattern was not observed for the end point of TE at low CHA 2 DS 2 -VASc scores (for a score of 1, 9.0% vs 5.3%; for a score of 2, 8.3% vs 6.6%; for a score of 3, 7.9% vs 7.7%; overall P<.001 for interaction). The absolute risk of TE was higher among patients without AF compared with patients with concomitant AF at high CHA 2 DS 2 -VASc scores (for a score of 4, 9.7% vs 8.2%; for a score of 5, 11.9% vs 11.2%; for a score of 6, 18.0% vs 14.9%; overall P<.001 for interaction) (see eTable 3 in the Supplement for more results on the test for interaction). The absolute risk increased in a comparable manner at high CHA 2 DS 2 -VASc scores (≥4), exhibiting a clear dose-response relationship. Similar patterns were observed after 5 years of follow-up (eFigure 1 in the Supplement).
The discriminatory properties of the CHA 2 DS 2 -VASc score depended on the choice of end point and the duration of follow-up ( Table 3) . In patients without AF, the CHA 2 DS 2 -VASc score showed moderate predictive ability for the end point of ischemic stroke (C statistics at 1-and 5-year follow-up, 0.67 [95% CI, 0.65-0.68] and 0.69 [95% CI, 0.67-0.69], respectively). In patients with AF, the predictive ability for the end point of ischemic stroke was also modest (C statistics at 1-and 5-year follow-up, 0.64 [95% CI, 0.61-0.67] and 0.71 [95% CI, 0.68-0.73], respectively). When using NPV to identify patients at low risk of ischemic stroke, TE, and death, the CHA 2 DS 2 -VASc score yielded NPVs around 90% at 1-year follow-up for patients with HF without AF (NPVs, 92% [95% CI, 91%-93%] for ischemic stroke, 88% [95% CI, 87%-89%] for TE, and 93% [95% CI, 92%-94%] for death). At 5-year follow-up, NPVs were strongly attenuated. In the sensitivity analysis, repeating the absolute and relative risk calculations after extending the definition of concomitant AF, we found very similar results as in the main analysis (eFigure 2 in the Supplement). When censoring patients with HF who were diagnosed with AF during follow-up, similar results were found and the conclusions remained the same as in the main analysis (eFigure 3 in the Supplement). In the split sample analysis, we found similar results for all end points in both the early and late study period as in the main analysis for patients without AF (eFigure 4 and eFigure 5 in the Supplement). However, for patients with AF, we found higher relative risks of all end points in the early study period compared with the main analysis but similar results for the absolute risks. The C statistics were similar in both the early and late study period and comparable with the main analysis as follows: (1) In the sensitivity analysis, when we included patients with COPD, the results were qualitatively similar for patients without AF, but the absolute risks for patients with AF were lower and the relative risks were higher compared with the main analysis. Thus, the conclusions remained the same (eFigure 6 in the Supplement).
Supplemental analysis of the association between each individual component of the CHA 2 DS 2 -VASc score and the risk of ischemic stroke is shown in eTable 4 in the Supplement. In patients both with and without AF, female sex was not associated with an increased risk of ischemic stroke. 
Discussion
In this cohort study, our principal findings were that (1) patients with HF had a high risk of ischemic stroke, TE, and death whether or not AF was present; (2) the CHA 2 DS 2 -VASc score was able to modestly predict these end points and had a moderately high NPV at 1-year follow-up; and (3) at high CHA 2 DS 2 -VASc scores (≥4), patients with HF without AF had high absolute risk of ischemic stroke, TE, and death, and the absolute risk increased in a comparable manner in patients with HF with and without AF, exhibiting a clear dose-response relationship. Indeed, the absolute risk of thromboembolic complications was higher among patients without AF compared with patients with concomitant AF at high CHA 2 DS 2 -VASc scores (≥4). To our knowledge, this is the first study to evaluate the predictive ability of the CHA 2 DS 2 -VASc score in estimating the risk of ischemic stroke, TE, and death in a population of patients with incident HF with and without AF.
Patients with HF and without AF are at increased risk of ischemic stroke and TE, and in recent randomized trials, these end points (which were secondary trial end points) were reduced by warfarin therapy. [28] [29] [30] In the Danish Diet, Cancer and
Health cohort, we previously demonstrated the high risk of stroke and mortality among patients with HF without AF, which was lower if warfarin therapy was prescribed. 4 Patients with HF have an increased risk of ischemic stroke, TE, and death regardless of whether AF is present. 28 In our study, one of our principal findings was that the absolute risk of ischemic stroke among patients without AF was about 1.5% per year or higher with CHA 2 DS 2 -VASc scores of 2 or higher, with associated 5-year absolute ischemic stroke risks in excess of 4% or more. Risks were even higher among the patients with HF with AF in our study. Similar absolute risks were found when stratifying analyses according to early and late study period, indicating a robustness of our findings to changes in standard HF diagnostic and treatment modes between 2000 and 2012. In the general AF population, a stroke risk of greater Error bars indicate 95% CIs. Numbers of patients contributing data in each group for CHA 2 DS 2 -VASc scores from 1 to 6, respectively, were as follows:
than 1% per year is often used as a cut point to identify patients in whom the benefits of long-term oral anticoagulation may outweigh the risks of bleeding. 31 In the present HF population, patients without AF with a CHA 2 DS 2 -VASc score of 2 or higher had a stroke risk greater than 1% per year. Although it is not clear whether this cut point would apply directly to the HF population without AF, our results may suggest that subgroups of patients with HF without AF and with 2 or more components of the CHA 2 DS 2 -VASc score besides HF are at high enough risk of ischemic stroke to benefit from anticoagulation therapy; especially with availability of the non-vitamin K antagonist oral anticoagulants. Our other principal finding is that in patients with HF with elevated CHA 2 DS 2 -VASc scores (≥4), the absolute risk of ischemic stroke, TE, and death was very high. At these high CHA 2 DS 2 -VASc scores, the absolute risk increased in a comparable manner in patients with HF with and without AF, exhibiting a clear dose-response relationship, so that the absolute risk of TE was even greater among patients without AF compared with those with concomitant AF. The poor prognosis of AF for ischemic stroke and death in patients with HF was evident in our study, but the observation that additional risk factors in patients with HF are particularly significant among those without AF is an important result. Indeed, preventative strategies to reduce ischemic stroke and TE risk in this large patient population require further investigation.
The C statistics demonstrated that the performance of the CHA 2 DS 2 -VASc score was dependent on the type of end point and the length of follow-up. In patients with HF without AF, the CHA 2 DS 2 -VASc score performed moderately in discriminating patients experiencing an ischemic stroke from stroke-free survivors. The C statistics for predicting "events" in this study are also comparable with other commonly used risk scores based on clinical risk factors (for example, the CHADS 2 score in AF). Although these initial results demonstrate a potential use of the score, the direct clinical utility of stroke risk stratification in patients with HF is an open question. In this high-risk population, all-cause mortality remains the key concern, as indicated by the very high mortality rates and the corresponding relatively poorer performance of the risk score for predicting events after 5 years of follow-up. On the other hand, CHA 2 DS 2 -VASc yielded a moderately high 1-year NPV for identifying patients at "low risk" of stroke or death (approximately 90%). This is consistent with the CHA 2 DS 2 -VASc score as a useful tool for identifying "low-risk" patients, as evident in various studies examining risks in AF patients. 32, 33 In our study, we found a less clear association between ischemic stroke risk and increasing CHA 2 DS 2 -VASc score among patients with HF and AF, exhibiting a possible J-shaped association or possibly no meaningful association, which could be due to the low event numbers with some of the scores. Furthermore, not all the individual components of the CHA 2 DS 2 -VASc score have been identified as established risk factors of ischemic stroke in the HF population without AF. Previous studies have even showed that some of these components are associated with a decreased ischemic stroke risk, 4, 26, 27 which our supplemental analysis also demonstrates. In spite of these previous findings, the CHA 2 DS 2 -VASc score was able to modestly predict the risk of ischemic stroke in our study. Future studies examining the individual drivers of risk derived from the CHA 2 DS 2 -VASc score are still needed. The major strengths of this study are the validated outcomes and large sample size uniquely possible with this type of cohort study. Selection into the study was not an issue because we investigated a nationwide population of patients with incident HF with and without AF, with limited loss to followup. We also accounted for competing risk of death, an important issue when investigating the performance of risk scores in populations with a high mortality. 13, 24 The study has some limitations. We were unable to distinguish between HF with preserved vs reduced ejection fraction or to estimate the functional classification/symptoms severity because we did not have access to echocardiograms. In a previous systematic review, whether a clinical diagnosis of with HF would also vary over time and with treatments. In addition, we investigated the risk in patients with incident HF, and our results may not relate to the general population of patients with HF. However, we also reported risks after 5 years of followup, and we believe these results are comparable with the general HF population. Because of the high mortality rate in the HF population (and therefore, the short follow-up in this study), we focused on the 1-year risks. The HF diagnosis has previously been validated with a sensitivity of 29%, a specificity of 99%, and a positive predictive value of 81%, 18 and based on the validation study we did not capture all patients with HF and also cannot be certain that all patients identified as having HF had definite HF, which could lead to imprecision in the risk estimates. However, we included only patients with a primary discharge diagnosis of HF to optimize the probability of including only correctly identified patients with HF.
We investigated a real-life population using nationwide registries in which we did not exclude severely ill patients (as typically done in clinical trials); thus, our study population includes patients with HF with several comorbidities predisposing for stroke events, and our event rates may be higher than that seen in clinical trials. Indeed, Nielsen and Chao 13 discussed the issue with different event rates observed from different populations. We cannot rule out that some patients without AF might have had undiagnosed AF because heart disease is associated with an increased risk of developing AF and AF is silent in up to a quarter of patients. In our sensitivity analyses, extending the AF definition and censoring if development of AF occurred during follow-up, we found similar results as in the main analysis. Additionally, our study population was ethnically and socially nondiverse. Thus, our study results might not be generalizable to more diverse HF populations. Furthermore, we excluded patients with HF younger than 50 years; accordingly, our findings may not apply to younger patients with HF.
We did not have information about smoking habits; however, we excluded patients with a diagnosis of COPD, which are primarily patients with an intensive smoking habit or history, and therefore, our results might not be valid for patients with COPD. However, in our sensitivity analysis, when we included patients with COPD, the conclusions remained the same.
Because of the nature of our nationwide registry study, follow-up depended on the National Civil Registration System, in which some deaths are likely to be attributable to an undiagnosed stroke. Finally, the diagnosis of ischemic stroke was defined by the Danish Hospital Discharge Register, and not all stroke end points have been defined by cerebral imaging; thus, the data did not allow classification of ischemic stroke types. However, the ischemic stroke diagnosis has previously been validated. 17 
Conclusions
Among patients with incident HF with or without AF, the CHA 2 DS 2 -VASc score was associated with risk of ischemic stroke, thromboembolism, and death. The absolute risk of thromboembolic complications was higher among patients without AF compared with patients with concomitant AF at high CHA 2 DS 2 -VASc scores. However, predictive accuracy was modest, and the clinical utility of the CHA 2 DS 2 -VASc score in patients with HF remains to be determined.
